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ABSTRACT 
 
 
 
UNDERSTANDING MYCOBACTERIUM ABSCESSUS IN CYSTIC FIBROSIS MICE  
 
 
 
Cystic fibrosis (CF) is caused by mutation of the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) gene, which normally encodes an ABC transporter-
class ion channel protein that allows chloride and thiocyanate ions transport across 
epithelial cell membranes. Thus, CFTR plays an important role in airway homeostasis. 
Mutations of CFTR in patients with CF leads to a defect in transport of chloride and 
thiocyanate ions by epithelial cells, resulting in a multi-system disorder that affects the 
respiratory tract, gastrointestinal tract, the endocrine system, among others. The 
epithelial cell dysfunction in the lungs of CF patients also leads to an impaired 
pulmonary defense mechanism, resulting in decreased bacterial clearance and chronic 
inflammation. In CF patients, lung disease due to non-tuberculous mycobacteria (NTM) 
— an environmental organisms found in soil, water, and biofilms — is one of the most 
feared complications. Among the NTM, the rapidly-growing Mycobacterium abscessus 
is particularly notorious given its intrinsic resistance to many antibiotics. The 
transmission of M. abscessus to humans occurs by wound contamination, airborne 
transmission, or ingestion. Despite the fact that M. abscessus infection is increasing 
worldwide, little is known about how M. abscessus causes disease. 
To improve our understanding of M. abscessus in CF patients, we set out to 
investigate the progression of M. abscessus infection in a CF mouse model by 
developing a reinfection mouse model using three different strains of “CF mouse” — 
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Beta-ENaC mice, Cftrtm1UNCTgN(FABPCFTR) mice and CFTRtm1UNC/ CFTRtm1UNC mice 
— to track the bacterial burden and organ pathology. Our results support the hypothesis 
that repeated infection with M. abscessus is more likely to result in disease progression 
and increased pathogenesis of the disease in CF mouse models. The high bacterial 
burden persisted in the lung after four infections in β-ENaC transgenic mice and 
CFTRtm1UNC/CFTRtm1UNC mice and maintained in the organs by day 30. 
Cftrtm1UNCTgN(FABPCFTR) mice tended to show slowly increasing bacterial burden in 
all organs. In summary, we demonstrate that  reinfection of the CF mouse models with 
M. abscessus is more likely to result in a sustained infection in the lungs associated with 
increased pulmonary pathology. 
Kridakorn Vongtongsalee, DVM 
Microbiology, Immunology, and Pathology Department 
Colorado State University 
Fort Collins, Colorado 
Spring 2019 
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CHAPTER 1 – LITERATURE REVIEW 
 
 
 
Introduction 
Cystic fibrosis (CF) is an autosomal recessive genetic disorder due to mutations 
of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, resulting 
in a defect in the transport of ions by epithelial cells in multiple organ systems, including 
the respiratory tract, gastrointestinal tract, reproductive tract, various exocrine organs, 
and the immune system [5, 6, 7]. CF has been observed in children ranging from one 
month old — the most life-threatening period for infants who have signs of malnutrition 
and poor weight gain — to adolescents [1]. CF has a significant impact on the patient’s 
quality of life. The incidence of CF for Caucasian populations is 1 in 2,500 whereas it is 
1 in 10,900 for Native Americans, 1 in 15,000 for Africans, and 1 in 35,000 for Asians [2, 
3, 15]. However, the clinical expression of CF is not differentiated by race but instead 
depends on age and genotypic CF genes [15]. 
Bacterial infection is a serious problem in CF patients as it is estimated that 80% 
to 95% of CF patients will eventually acquire chronic bacterial lung infections and 
resultant tissue-damaging pulmonary inflammation [3]. While lung infections with 
pyogenic bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus are 
more common infections in the lungs of CF patients, lung disease due to non-
tuberculous mycobacteria (NTM) is particularly feared because of their intrinsic drug 
resistance. Among the NTM, Mycobacterium abscessus is particularly notorious 
because it is highly difficult to completely eradicate with available antibiotics [4]. Most 
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children with CF who recover from M. abscessus have a high risk of reinfection, disease 
progression, and mortality. 
The immune system, both in cellular and humoral immunity, as it relates to CF is 
of great interest to scientists and clinicians. This thesis is focused on evaluating the 
bacterial burden and pulmonary organ pathogenesis in CF mouse models exposed to 
repeated infections with M. abscessus. Additionally, it is intended that these 
experiments will provide improved understanding of the potential M. abscessus 
pathogenesis due to reinfection in the CF host. 
 
 
 
Cystic Fibrosis Characteristics 
Under normal conditions, the CFTR gene is located on the apical membrane 
epithelial cells, encodes the CFTR protein channel which controls chloride ion (Cl-) 
transportation in the body. The CFTR gene results in an ABC transporter-class ion 
channel protein that normally allows for chloride and thiocyanate ions to cross epithelial 
cell membranes. The CFTR protein channel, during normal regulation will secrete Cl- 
out of the cell. CFTR also regulates the sodium ion (Na+) and thiocyanate ion and 
associates with the epithelial sodium channel (ENaC) in pulmonary epithelium to 
reabsorbs Na+ into the cell. ENaC is a heteromultimeric protein composed of three 
subunits (α, β, and γ), located on the cilial surface, has an important role in modulating 
the airway surface liquid (ASL) clearance and essential for cilial transport of mucus in 
the respiratory tract [84]. The defective CFTR-mediated Cl- secretion and increased 
ENaC-mediated Na+ absorption contribute to the pathogenesis of CF airway disease 
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which loss of normal regulation by CFTR and alter the airway ion transport [81-82]. 
Overexpression of ENaC shows hyperabsorption of Na+ and ASL depletion leads to 
increased mucus accumulation to airway surface and increased airway inflammation 
[81]. 
The regulation of CFTR and ENaC interaction in the respiratory airway has been 
studied because of the CF involvement. It was indicated that the indirect effect of CFTR 
genes influences ENaC activity by coexpressed with cyclic adenosine monophosphate 
(cAMP)-dependent pathway resulting in increased intracellular Cl- concentration and 
correlated to the inhibitory effects of CFTR on ENaC [83-85]. Mutation in the CFTR 
gene changes the regulation of ion homeostasis in the cell. Dysfunction of CFTR in CF 
patients leads to decreased inhibition of ENaC by lacking of chloride and thiocyanate 
ions crossing the epithelial cell membranes and encouraged ENaC activity resulting in 
excessive highly viscous mucus formation and secondary ciliary dysfunction in multi-
system, including respiratory tract, gastrointestinal tract and endocrine system [3, 8, 9, 
84]. 
The recent studies found the novel cell populations, pulmonary ionocytes, the 
rare specialized pulmonary cells that regulate ion transport and hydration in the 
epithelial surface, are a major source of CFTR activity in the respiratory tract which 
express higher levels of CFTR genes than other lung cell types. The pulmonary 
ionocytes co-expresses highly CFTR and Foxi1 expression, which regulates the 
expression of multiple subunits of V-ATPase. V-ATPase is necessary for ion 
transportation and controls fluid pH. These new cell type in the airway epithelium have 
been discovered only 1-2% of the cell population in mouse trachea and primary human 
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bronchial tissue by using the single-cell RNA sequencing technology to analyze Foxi1 
expression in the individual cells. This new discovery shows that Foxi1+ CFTR+ 
ionocytes are located in multiple layers of the respiratory tract and appears to play a 
critical role in CFTR expression which is responsible for the pathogenesis of CF [86-87]. 
To date, approximately 1,600 mutations have been identified in the CFTR gene 
[10]. The severity of the defects are highly related to the type of gene mutations. The 
CFTR mutations can be categorized into six classes based on the mechanism of the 
channel function defect. These CFTR mutation classes are associated with either the 
absence, decreased expression, or dysfunction of the CFTR protein, resulting in diverse 
physiological phenotypes in CF patients [8, 10]. 
A class 1 mutation is the premature insertion of the stop codon into the CFTR 
gene which affects protein expression. This CFTR mutation will express degraded 
CFTR proteins in the endoplasmic reticulum (ER). The most common mutation of the 
CFTR gene, a Class 2 mutation, is the missense mutation wherein phenylalanine at 
position 508 of the CFTR protein is deleted (ΔF508). The ΔF508 allele is found in 70% 
of all CFTR mutations [3]. These mutations cause misfolded CFTR protein, resulting in 
CFTR protein being degraded in the endoplasmic reticulum (ER). As the result, CFTR 
proteins are not expressed at the apical surface of epithelial cells. Class 3 mutation, 
known as a gating defect, is a missense mutation result in blocking Cl- channel. Class 4 
mutations reduce Cl- channels. Class 5 mutations reduce functional CFTR synthesis, 
and class 6 mutations decrease the half-life of CFTR proteins. All of these defects 
cause Cl- ion channel transportation impairment which can affect the ENaC at the 
epithelial cells throughout the body [3, 8, 10].  
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The symptoms and signs of CF vary from individual to individual. In some cases, 
CF can be diagnosed with in the first month of life. However, the disease may not 
progress or develop until adulthood. Eventually, pulmonary issues become more 
obvious and serious in the majority of CF patients. Normally, the mucociliary function 
can clear all mucus, debris, and thus help airway bacterial infections. However, in CF 
patients, non-functional mucociliary function results in viscous mucus secretion that are 
unable to be cleared, chronic airway and parenchymal inflammation, and finally 
manifesting as bronchiectasis and lung fibrosis. 
Approximately 80% of patients with CF will eventually acquire chronic bacterial 
infections in the lungs that include P. aeruginosa, S. aureus, Haemophilus influenza and 
NTM [11]. One mechanism for host immune evasion by these organism is through 
production of biofilms. The prevalence of NTM isolation from CF patients has been 
reported to be 4% to 24%, depending on the geographical region and patient population 
[12]. More importantly, the most prevalent NTM that has been isolated is M. abscessus 
[4]. Chronic M. abscessus infection and inflammation cause bronchial wall damage and 
dilation (bronchiectasis) leading to respiratory failure from repeated CF exacerbations, 
ultimately causing respiratory insufficiency and death. 
Although respiratory problems related to CF are still the major problem, an 
extrapulmonary clinical manifestation also can be present in CF patients, such as the 
impairment of gastrointestinal tract function. Meconium ileum due to increased viscosity 
of intestinal mucus may cause intestinal obstruction, occurs in 13% to 17% of CF 
newborns [1]. Malnutrition, poor weight gain, and growth failure may occur in early 
childhood due to pancreatic insufficiency from the thick secretions that block the 
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pancreatic ducts. As a result, pancreas-derived digestive enzymes are inadequately 
secreted into the intestinal tract, impairing absorption of nutrients. Furthermore, the 
retained digestive enzymes in the pancreas and the local inflammation in the pancreas 
lead to further damage and fibrosis of the pancreas, culminating in a vicious cycle of 
pancreatic insufficiency. 
Mutation of CFTR also impacts the reproductive system. Infertility is found in 
more than 95% of male CF subjects [13]. CFTR functions in association with the HCO3– 
channel to play an important role in sperm capacitation. The mutation of the CFTR gene 
causes malformation of the vas deferens, further reducing fertility. Infertility in women 
has also been observed in CF patients. Mutated CFTR, in association with sex hormone 
abnormality, and viscous mucus production in the female reproductive tract, involving 
the cervix, ovary, oviduct, and uterus. Reduced fertility due to mutated CFTR may also 
be due to inadequate fluid regulation in the female reproductive tract, the small size of 
female reproductive tissues, decreased ovulation rates, and abnormality of the estrous 
cycle [14]. 
 
 
 
Cystic Fibrosis Immune Dysregulation 
CFTR dysfunction also affects many components of both cellular and humoral 
immunity, contributing to many of the medical problems seen in CF patients [7, 9]. 
Chronic lung disease due to CF is the most serious and challenging management 
problem and adversely affects the quality of life and lifespan [7]. Affected infants may 
not show any signs or symptoms at birth, but then later manifest the symptoms of CF 
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pulmonary disease. Excessive inflammatory reaction in the airway caused by the 
immunostimulatory pathogen-associated molecular patterns (PAMPs) results in 
increased proinflammatory cytokines and chemokines (TNF and CXCL-8), and 
increased polymorphonuclear neutrophil (PMN) accumulation [16-17]. Other studies 
found that increased bacterial presence in CF airways induces biofilm formation, as well 
as increased recruitment of leukocytes into the lungs [18-22]. Neutrophils are rapidly 
recruited into the inflammation site and response to PAMPs for clearing the bacterial 
infection. However, the ongoing chronic inflammation in CF patient and the neutrophil 
recruitment still continue over time. The isolated neutrophil from CF and COPD patients 
in the pulmonary airways is impaired to response by LPS stimulation and impaired 
antibacterial killing capacities. This sustained and excessive neutrophil accumulation in 
lung tissue contributes to excessive lung inflammation and lung tissue damage [18, 23]. 
The CFTR defect results in increased NF-κB signaling and downstream pro-
inflammatory cascades, including Ca2+-dependent signaling, nuclear factor of activated 
T-cell (NFAT) transcription, and mitogen-activated protein kinase (MAPK)-dependent 
activation of activator protein-1 (AP-1) [24-28].  
Another PAMP receptor, TLR4 is displayed on the airway epithelial cell surfaces 
and via MyD88, activates the Trif-dependent pathway. Trif signaling increases the 
production of type I interferon (IFNs) [29], including IFN-α and IFN-β, that are mainly 
involved in the infection clearance in the airway. However, these processes seem to be 
interfered in CF cells. TLR4 is expressed at lower levels on the CF cells surface and 
lack of antigen recognition leads to a weak signaling to MyD88 and Trif signaling [23].  
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Decreased Trif-dependent effectors cells impacted by dysfunctional CFTR genes may 
contribute to poor bacterial clearance and chronic infection of CF lungs [23]. 
Studies evaluating the CF airway demonstrated defects in cell function of 
neutrophils, macrophages, dendritic cells and T cells [30-32]. The excessive PMN 
migration to the lungs caused impaired phagocytosis and delayed apoptosis of 
neutrophils [30-32]. Excessive neutrophil accumulation in the airway also resulted in 
protease-rich degranulation, and neutrophil extracellular traps (NET) [34-36] 
contributing to exaggerated inflammatory tissue damage [16, 33, 37-38] and decreased 
lung function. 
Alveolar macrophages play an important role in the anti-bacterial host defense, 
as well as removal of apoptotic cells. The number of alveolar macrophages in CF 
patients has shown to be higher than in non-CF individuals [39], correlated with the 
increased concentration of CCL-2 [39-40]. In the innate inflammatory process, there are 
two subpopulations of macrophages acting in multifunctional capacities. Classically 
activated macrophages secrete high concentrations of pro-inflammatory cytokines and 
anti-microbial products. In contrast, some forms of alternatively-activated macrophages 
have more immunosuppressive function, albeit this paradigm is getting much more 
complex. Studies evaluating the macrophage polarization in CF patients showed that in 
the CF pulmonary airway without any inflammatory stimulant there is excessive 
expression of classical activation leading to a pro-inflammatory state [41] and inducing a 
hyper-inflammatory response in the CF airway leading to pulmonary tissue damage 
through activation of the NF-κB and MAPK signaling pathways [42-44]. 
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Classification of Nontuberculous Mycobacterial strains 
Globally, NTM infection is increasing in CF patients [47]. M. abscessus is a rapid-
growing NTM species that causes infection affecting many different organ types, 
including the central nervous system infections, skin and soft tissues, eyes, 
disseminated diseases and bacteremia in those who are severely immunocompromised 
such as those with untreated AIDS, but is found relatively frequently as a respiratory 
infection in susceptible individuals such as those with CF [45]. It is an acid-fast bacillus 
that is commonly found in soil and water. Due to their intrinsic multidrug resistance 
(MDR), they may cause recalcitrant infections in either the lungs or extra-pulmonary 
sites [12]. M. abscessus complex can be divided into three subspecies: M. abscessus 
subspecies massiliense, M. abscessus subspecies abscessus, and M. abscessus 
subspecies bolletii [46]. Laboratory identification of M. abscessus complex relies on the 
phenotypic method, such as biochemical testing, and molecular sequencing to 
differentiate between subspecies. M. abscessus is a quickly evolving, emerging human 
pathogen whose impact has grown considerably in the past decade [47]. Due to M. 
abscessus is a rapid-growing NTM, the genetic mutation for resistance to antibiotics is 
commonly occur in M. abscessus strains. The global distribution of M. abscessus 
strains from CF individuals found that the most dominant clones are M. abscessus 
clustered [78]. Moreover, Macrolide and aminoglycoside resistance in M. abscessus has 
been identified by the whole genome sequencing from this M. abscessus clustered [88]. 
 Pulmonary disease is caused by inhalation of aerosolized M. abscessus 
transmission or direct contact with contaminated material. Additionally, infections 
caused by M. abscessus have been reported in contaminated materials and improper 
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surgical procedures, such as during cosmetic surgery, or the use of contaminated 
surgical equipment. M. abscessus may also be found in wound infections of post-
operative patients [45]. While immunocompromised hosts are susceptible to M. 
abscessus infection, immunocompetent hosts may also be infected with M. abscessus 
[48]. Abnormal lung structure and pulmonary environments induce host susceptibility to 
M. abscessus infection [47, 49]. 
M. abscessus subspecies are inherently drug resistant. The Clinical and 
Laboratory Standard Institute (CLSI) list effective agents against M. abscessus complex 
as clarithromycin, amikacin, and cefoxitin. Mycobacteria have a complex cell wall made 
up of peptidoglycolipid containing mycolic acid and peptidoglycan which likely 
contributes to the mechanism of drug resistance and pathogenic virulence. Also, the 
recognition of functional erythromycin ribosome methyltransferase (erm) gene leads to 
inducible macrolide resistance through the 23s ribosomal RNA methylation [45, 50]. 
Additionally, biofilm formation allows M. abscessus to colonize and persist in the 
pulmonary environment. M. abscessus complex is resistant to many antimicrobial drugs 
that require prolonged treatment resulting in toxicity and poor therapeutic treatment 
outcomes [50]. 
 
 
 
Aims 
The purpose of my thesis work is to investigate if repeated infection of various 
CF mouse models with M. abscessus influences the bacterial burden and organ 
pathology. We hypothesize that repeated infections with M. abscessus is more 
11 
 
likely to result in increased pathogenesis of disease in CF mouse models, as 
evinced by increased and sustained bacterial burden as well as worse organ 
pathology than a single infection. If our hypothesis is supported by experimental 
evidence, it may further increase public health measures to limit infection since NTM are 
ubiquitous in the environment and exposure to them are likely pervasive. We will test 
this hypothesis with the following Aims: 
Aim 1: Develop in CF mice a model of reinfection with sub-optimal doses of 
M. abscessus and quantify the bacterial burden. 
Aim 2: Analyze the lung histopathology of CF mice reinfected with M. 
abscessus. 
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CHAPTER 2 – MATERIALS AND METHODS 
 
 
 
Preparation of M. abscessus OM194 stock 
M. abscessus used in this study was an outbreak strain obtained from Dr. Andres 
Floto (University of Cambridge, UK): M. abscessus subsp. massiliense OM194. M. 
abscessus OM194 is an outbreak strain that has a rough colony morphology and 
produces biofilms in vivo. This OM194 strain is a clinical isolate of the subspecies 
massiliense. M. abscessus were grown in 7H9 broth with Glycerol, Dubos Oleic Albumin 
Complex (OADC), and Tween 80 to an optical density (OD) of 1.0, or a concentration of 
approximately 1 x 108 CFU/mL. The culture was then centrifuged at 2,800 g for 10 
minutes at 23°C. The bacterial cell pellet was resuspended in fresh 7H9 broth with 
glycerol, OADC, and Tween 80. This solution was again centrifuged for 5 minutes at 
2,800 g at 23°C. The supernatant was discarded, and the remaining pellet saved. 
Finally, 1.5 mL of bacterial culture was pipetted into glass vials, which were plugged and 
sealed. A titer was obtained for each final culture, and labelled vials were stored in 
cryovial boxes at -80°C. 
 
 
 
Animal Model 
Infection experiments were performed in three Cystic Fibrosis mouse models (1) 
Cftrtm1UNC/Cftrtm1UNC mice, (2) Cftrtm1UNCTgN(FABPCFTR) mice, and (3) β-ENaC 
transgenic mice. These mouse models were obtained from the Jackson Laboratories. 
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(1) CFTRtm1UNC/ CFTRtm1UNC mouse model was backcrossed onto the C57BL/6 
genetic background, called CFTR Knockout, inserted the stop codon into exon 10 of the 
CFTR coding sequence (S489X mutation) which generated null mutation of CFTR gene 
[6].  
(2) Cftrtm1UNCTgN(FABPCFTR) mouse model was knockout for murine CFTR 
gene but expressed CFTR gene into the intestinal villous epithelial cells under the 
control of rat intestinal fatty acid binding protein (FABP) promoter. These transgenic 
mouse models can prevent the gut obstruction and intestinal pathology from the 
defective CFTR gene, and improve the survival rate in CFTR-Knockout mouse model 
[6, 54]. 
(3) β-ENaC transgenic mouse model was an overexpressing of the β subunit of 
airway-specific epithelial Na+ Channel (β-ENaC) mouse model, which allow to mimic 
increased ENaC activities in CF airways and develop the cystic fibrosis-like lung 
disease [67, 81]. 
 
 
 
Animal Infection 
CF mice were infected with an intratracheal infection using a microsprayer of 35 
μL containing 1.0 x 106 CFUs of M. abscessus OM194. The M. abscessus inoculum 
was prepared by thawing the bacterial vial. Thereafter, the mycobacterial suspension 
was obtained from the vial with a 1-ml tuberculin syringe fitted with a 26.5-gauge needle 
and expelled back into the vial. This procedure was repeated 20 times without removing 
the needle to mix the suspension and break up any small clumps of bacilli. 
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Mice were exposed to bacteria by intra-tracheal infection once, twice, thrice, and 
four times to establish a progressive infection. The time duration between infections is 
24 hours. A group size of n=4 was sufficient given the power analysis referenced in 
section 2.6. We and staff at Colorado State University’s Laboratory Animal Resources 
(LAR) monitored the mice daily for signs of distress indicating sickness from the 
bacterial infection. If mice became distressed, they were humanely euthanized by CO2 
inhalation, and their whole lungs, livers, and spleens were harvested. 
 
 
 
Bacterial Burden 
 On day 5, day 15, and day 30 post-infection with the M. abscessus subsp. 
massiliense OM194, 4 mice from each group were humanely euthanized by using 20% 
carbon dioxide (CO2) euthanasia and their whole lungs, spleens, and livers were 
harvested to determine the bacterial burden baseline at each time point. Organs were 
homogenized in 5 mL of phosphate-buffered saline (PBS), and serial dilutions were 
plated on nutrient 7H11 agar and TSA for 1 week at 30°C, and thereafter CFU were 
enumerated. 
 
 
 
Organ Histology 
The whole lungs and spleens from M. abscessus subsp. massiliense OM194 
infected mice were fixed in 10% formalin, and left inside a biosafety level 3 (BSL-3) 
barrier at CSU for 2 weeks at 4°C. The organs were then transported to a biosafety 
15 
 
level 2 (BSL-2) laboratory at CSU and the 10% formalin was discarded from the organs. 
Then the organs were placed in 70% ethanol at 4°C for at least 2 days. 
Next, the 70% ethanol was discarded from the organs, and the organs were 
immersed in 1XPBS at 4° C and sent to the Experimental Pathology Core Facility at 
CSU Veterinary Diagnostic Laboratories and Diagnostic Medicine Center for 
histopathological analysis with Hematoxylin and Eosin (H&E) stains and Ziehl-Neelsen 
stain (Acid Fast Bacillus (AFB) stains). 
 
 
 
Statistical Analysis 
Bacterial burdens in the M. abscessus subsp. massiliense OM194 infected 
animal organs were analyzed with GraphPad Prism version 4 (GraphPad Software, San 
Diego, CA), using analysis of variance (ANOVA) and Dunnett and Tukey multiple 
comparison tests. Data are presented using the mean values (n = 4) plus or minus the 
standard error of the mean (SEM). Significance was considered below a P value of 
p<0.050. 
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CHAPTER 3 – ANIMAL MODEL DEVELOPMENT 
 
 
 
Development of Cystic Fibrosis Mouse Models 
Recent research has found that among wild-type animal models and the 
defective animal models are all have different susceptibility to M. abscessus infection, 
many are able to clear bacterial infection quickly, do not achieve acute infection, and 
develop the progressive disease, as shown in Table 1 [68]. Several genetically modified 
mouse strains have been developed for use as animal models of Cystic Fibrosis [6, 51]. 
These CF mouse models allow to exhibit a high level of M. abscessus infection and 
become a good model to study the bacterial infection in the CF patient. 
Generating the CF mouse models designed simply to disrupt the functional 
CFTR gene expression to create the null mutation or produce low level of CFTR mRNA, 
as shown in Table 2. The primary phenotypes from developing the CF animal models, 
including airway and intestinal electrophysiological defects, reduced fertility, and 
intestinal obstruction, which can mimic the CF in human. However, the characteristic of 
CFTR mutant mouse models appeared an abnormal immune profile which fails to thrive 
and increased the mortality rate in the early period of life. The null CFTR expression 
mouse model generated the loss of CFTR function, which can not detect CFTR mRNA 
in these mice [8]. The severity of intestinal pathology was affected to the survival rate of 
null mouse models. The hypomorphic strains and point mutation strains mouse models 
have been developed to improve nutrient absorption and increase lifespan in CF mice. 
These CF mouse models expressed low level of the CFTR mRNA [6]. The generation of 
transgenic CF mouse models  
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Table 1. Animal models were screened by using intravenous infection (i.v.) for susceptibility to M. abscessus infection. 
Snimal models which maintained a high level of infection are in blue, animal models which cleared the bacterial infection 
are in red, and models which have not been tested yet are in black [68]. 
Key: GKO, Gamma-Interferon knockout; MyD88, Myeloid differentiation primary response gene 88; SCID, Severe 
Combined immunodeficient; NOS2, Nitric Oxide Synthase 2; SOD, Superoxide Dismutase; TLR, Toll-like Receptor; GM-
CSF, Granulocyte-Macrophage Colony-Stimulating Factor; TNFR, Tumor Necrosis Factor Receptor; IL, Interleukin; Lep, 
Leptin 
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Table 2. Genetically modified mouse strains have been developed for use as animal 
models of cystic fibrosis [6, 51]. 
Key: R, Replacement; I, Insertion; Ex, Exon; M, Methionine; Y, Tyrosine; F, 
Phenylalanine; G, Glycine; D, Aspatic acid; R, Arginine; H, Histidine 
*Tg(FABPCFTR) strain is a gut-corrected CFTR-knockout mouse model; FABP, Rat 
Intestinal Fatty Acid Binding Protein; CFTR, Cystic Fibrosis Transmembrane 
Conductance Regulator. 
**Tg(CCSPScnn1b) strain is also referred to as β-ENaC overexpression mouse model; 
CCSP, Clara Cell Secretory Protein; Scnn1b, Sodium Channel Epithelial 1 Beta 
Subunit. 
 
CF mouse strain Mutation 
Null mutation   
Cftrtm1Unc S489X Ex10 R 
Cftrtm1Cam R487X Ex10 R 
Cftrtm1Hsc M1X Ex1 R 
Cftrtm3Bay Ex2 R 
Cftrtm3Uth Y122X Ex4 R 
Hypomorphic mutation   
Cftrtm1Hgu Ex10 I 
Cftrtm1Bay Ex3 I 
F508del mutation   
Cftrtm2Cam F508del R 
Cftrtm1Kth F508del R 
Cftrtm1Eur F508del 
Other point mutations   
Cftrtm2Hgu G551D R 
Cftrtm3Hgu G480C 
Cftrtm2Uth R117H R 
Transgenes   
Tg(FABPCFTR)* CFTR 
Tg(CCSPScnn1b)** Scnn1b 
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was developed to increased survival rate of CF mouse models, which can mimic the CF 
lung disease in CF individuals [6, 51]. 
While some mouse models were discovered that demonstrate a susceptibility to 
infection and maintain a high level of M. abscessus group strains, including the CF 
mouse models with structural defects, CFTRtm1UNC/CFTRtm1UNC mice, 
Cftrtm1UNCTgN(FABPCFTR) mice, and β-ENaC transgenic mice [68]. The CF mouse 
model immune defects in the lung are shown in Table 3. 
CFTRtm1UNC knockout mouse model shows abnormal cAMP-mediated chloride 
ion transport of epithelial tissue in the respiratory tract and gastrointestinal tract, 
similar to CF patients [8, 52]. Severe intestinal complications, including intestinal 
obstruction, develop in CFTRtm1UNC knockout mice leading to low survival rate in this CF 
mouse strain. Therefore, Cftrtm1UNCTgN(FABPCFTR) mice which have a corrected lethal 
intestinal defect by using the rat intestinal fatty acid-binding protein (FABP) gene 
promoter for expression in intestinal epithelial cells [6, 51, 54]. This mouse model shows 
the expression of the intestinal villi and can rescue CF intestinal pathology [6, 51, 53].  
Lastly, the β-ENaC transgenic mice are Cystic Fibrosis-like mouse models that 
are genetically modified to produce overexpression the β-subunit of epithelial sodium 
channels (ENaC). The ENaC overexpression in mice resulting in deplete the airway 
surface layer, reduce mucus clearance, and develop CF ion transportation 
pathophysiology in the lung [67], similar to the typical features of early lung disease in 
CF individuals [55]. These three CF mouse models have been screened in development 
of a reinfection model. 
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Table 3. Cystic Fibrosis mouse models screened to develop a reinfection model. Three CF mouse models were used in 
this study, including (1) CFTRtm1UNC/CFTRtm1UNC, (2) Cftrtm1UNCTgN(FABPCFTR), and (3) β-ENaC transgenic mice.  
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In this study, using sub-optimal doses of M. abscessus 1.0 x 106 CFU/mouse, 
Figure 1 shows a low bacterial load in the lungs, spleen and liver after one infection 
between day 5 and day 15 in the Cftrtm1UNCTgN(FABPCFTR) mice. Also, in the 
CFTRtm1UNC/CFTRtm1UNC mice and β-ENaC transgenic mice, the bacterial burden tends 
to decrease after primary infection (Figure 1). Thus, additional infections (two infections) 
were administered to the CF mouse models using, resulting in an early higher bacterial 
burden in all three CF mouse models, which overtime resulted in bacterial clearance 
between 15 and 30 days in the spleen and liver. Although, it must be noted the bacterial 
burden in the lung of CFTRtm1UNC/CFTRtm1UNC mice and β-ENaC transgenic mice was 
still persistent (Figure 2). The CF models were exposed to 3 infections resulting in 
showed a higher bacterial burden between 5 and 25 days, however bacterial clearance 
resulted on day 30 in the Cftrtm1UNCTgN(FABPCFTR) mice and CFTRtm1UNC/CFTRtm1UNC 
mice. However, the β-ENaC transgenic mice demonstrated bacterial persistance (Figure 
3).  
Of the three CF mouse models, β-ENaC transgenic mice exhibited the highest 
levels of infection in the lung after four times infections with M. abscessus subsp. 
massiliense OM194. Figure 4 shows a steady increase in bacterial load in all three 
mouse models. Cftrtm1UNCTgN(FABPCFTR) mice tended to show slowly increase 
bacterial burden in all organs. CFTRtm1UNC/CFTRtm1UNC mice and β-ENaC transgenic 
mice tend to exhibit increased CFUs, especially in the lung. Hence, the multiple 
reinfections resulted in progressive M. abscessus pulmonary infection. 
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Pathogenesis of M. abscessus in Cystic Fibrosis Mouse Models 
Lung pathology of CFTRtm1UNC/CFTRtm1UNC mice, Cftrtm1UNCTgN(FABPCFTR) 
mice, and β-ENaC transgenic mice infected with four infections of Mycobacterium 
abscessus OM194 strain were stained with hematoxylin and eosin-stained (H&E) and 
were determined at day 5, day 15 and day 30 after reinfection. 
As early as 5 days post-infection, as shown in figure 5, the influx of cells to the 
sites of infection are evident in all three CF mouse models. We observed small and 
moderate inflammatory cells influx into the site of infection in Cftrtm1UNCTgN(FABPCFTR) 
and CFTRtm1UNC/CFTRtm1UNC mouse, respectively. The β-ENaC transgenic mouse 
exhibited the largest influx of inflammatory cells than the other two mice. 
As the disease progressed on day 15, as shown in figure 6, increased 
inflammatory cell infiltration in the site of infection and granuloma formation are 
observed. A significant increase in foci of inflammatory cells are evident and clearly 
increased granuloma development in the CFTRtm1UNC/CFTRtm1UNC mice and β-ENaC 
transgenic mice. 
Infection with M. abscessus OM194 strain for 30 days resulted in increased size 
and numbers of granuloma formation in all three CF mouse models, as shown in figure 
7. The severity of pulmonary pathology was less in the Cftrtm1UNCTgN(FABPCFTR) and 
CFTRtm1UNC/CFTRtm1UNC mouse models than compared to the β-ENaC transgenic mice 
at 30 days after reinfection. M. abscessus infected in β-ENaC transgenic mice exhibited 
more severe lung consolidation and increased size and number of granulomatous tissue 
upon examination of lung histology due to coalescence of granulomas in the lungs and 
increased inflammation. 
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Figure 1. Bacterial Burden after One Infection. Primary infection results in lower bacterial load and clearance. 
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Figure 2. Bacterial Burden after Two Infections. Two infections result in an early higher bacterial load and clearance in 
spleens and livers. 
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Figure 3. Bacterial Burden after Three Infections. Three infections result in higher lung bacterial burdens and clearance in 
spleens and livers. 
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Figure 4. Progressive Infection after Four Infections. Multiple reinfections result in progressive pulmonary infection.
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CFTRtm1UNC-TgN (FABPCFTR) 
  
B6CFTRtm1UNC/ CFTRtm1UNC 
 
βENaC overexpressing 
(β-ENaC Tg) 
  
Figure 5. Organ Histology analysis of pulmonary tissue from Mycobacterium abscessus 
reinfection in cystic fibrosis mice at day5; Magnifications, 1X (left), and 20X (right). 
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CFTRtm1UNC-TgN (FABPCFTR) 
  
B6CFTRtm1UNC/ CFTRtm1UNC 
 
βENaC overexpressing 
(β-ENaC Tg) 
 
Figure 6. Organ Histology analysis of pulmonary tissue from Mycobacterium abscessus 
reinfection in cystic fibrosis mice at day15; Magnifications, 1X (left), and 20X (right). 
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CFTRtm1UNC-TgN (FABPCFTR) 
 
B6CFTRtm1UNC/ CFTRtm1UNC 
 
βENaC overexpressing 
(β-ENaC Tg) 
 
Figure 7. Organ Histology analysis of pulmonary tissue from Mycobacterium abscessus 
reinfection in cystic fibrosis mice at day30; Magnifications, 1X (left), and 20X (right). 
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CHAPTER 4 – CONCLUSION 
 
 
 
 To investigate the numbers of sub-optimal M. abscessus pulmonary infections 
required to develop progressive disease in CF mouse models, we set out to screen 
three CF mouse strains to model M. abscessus reinfection in CF individuals. We 
observed in all three Cystic Fibrosis mouse models that were exposed to four sequential 
pulmonary infections of M. abscessus OM194 resulted in progressive pulmonary 
disease which supports our hypothesis that reinfection of NTM from the environment is 
more likely to result in disease progression in the CF mouse model. In this study, we 
found that four sequential exposures with sub-optimal numbers of M. abscessus 
OM194, the CFTRtm1UNC/CFTRtm1UNC mice, Cftrtm1UNCTgN(FABPCFTR) mice, and β-
ENaC transgenic mice developed a progressive infection denoted by increased 
bacterial burden in lungs, spleens and livers and pulmonary pathology denoted by 
increased number and size of the granulomatous inflammation. 
Over the last ten years, the NTM species have resulted in quickly evolving and 
emerging serious pulmonary infections, especially among patients that are 
immunocompromised and in patients with structural lung disease such as chronic 
obstructive pulmonary disease, bronchiectasis, and cystic fibrosis. This becomes a 
major threat to the patient’s health. The detection rate of NTM-positive culture from 
individuals with CF has increased remarkably over time in USA and Europe [47, 69-72]. 
The human environment, natural inhabitants of natural waters, engineered water 
systems and soils, have been observed as a major sources of transmissible pathogenic 
NTMs, and thus it is generally accepted that NTM infection was acquired through 
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environmental contamination [73-77]. Moreover, in the previous study by Bryant, et al. 
strong evidence was found of indirect human-to-human transmission of M. abscessus 
within CF treatment facilities, indicating that the long-distance spread of M. abscessus 
are being transmitted by fomites [78]. Also, Dr. Jackson and Dr. Ordway studied the 
virulence and pathogenicity of M. abscessus subsp massiliense epidemic strain, 
Brazilian BRA100 strain M. massiliense CRM-0019, which was shown that the outbreak 
strain of M. abscessus subsp massiliense is particularly virulent in part because of 
increased resistance to the treatment [79]. Consequently, repeated exposure of 
exogenous infections by contact with pathogenic NTMs from the environment may allow 
for the bacterial genetic adaptation, and influence the dissemination and development of 
NTMs to become a lung pathogen and lead to progressive pulmonary disease in CF 
individuals [80]. It is important to have CF mouse models to study the quantities of 
repeated inhaled M. abscessus required for development of progressive infection and 
ultimately disease resulting in severe lung tissue pathology, and pulmonary 
inflammation. Also, these could be helpful for testing experimental therapies prior to 
clinical trials. 
In our study, we found that β-ENaC transgenic mice achieved the highest level of 
susceptibility to a progressive disease after four infections. The high bacterial burden 
persisted after four infections in β-ENaC transgenic mice and maintained in the organs 
by day 30, indicating that these mice are unable to control M. abscessus with adaptive 
or innate immune response. This implies that β-ENaC transgenic mice are the best 
model to mimic CF individuals with NTM infection. β-ENaC transgenic mice are a 
functional candidate for testing the novel anti-mycobacterial drug for CF patients 
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because of the high-level of disease progression in β-ENaC transgenic mice after four 
infections. 
Additionally, we found that the β-ENaC transgenic mice and 
CFTRtm1UNC/CFTRtm1UNC mice developed lung pathology in the disease and progressed 
on day 15 and day 30 post-reinfections. Since humans develop pulmonary infection in 
both necrotizing and non-necrotizing granulomas, the β-ENaC transgenic mouse and 
CFTRtm1UNC/CFTRtm1UNC mouse models are useful to study the organ histopathology 
observed in CF patients. 
According to the National Jewish Health, the survival rate of CF patients has 
been increased in over the past three decades [89] since the CF animal model has 
been developed to improve quality of life and help to the development of the novel 
treatment for CF individuals. Animal models of CF are important for human diseases 
which is help to the further understanding in the mechanism of CF disease progression 
and CF pathology. However, the use of CF mouse models is limited by short life span of 
CF mice, which may not develop the chronic bacterial infection or chronic lung disease, 
unlike CF individuals. In human, chronic bacterial infection involves in the progressive 
and irreversible damage in the respiratory system remain the most prominent cause of 
elevated morbidity and mortality in CF. Also, the recurrent bacterial infection due to the 
antibiotic resistance is problematic for CF, which fails to cure pulmonary exacerbations 
and infections [3]. These problems remain to be life-threatening implications that might 
be solved by the novel therapeutic treatment.  
The impact of the bacterial reinfection in CF patients is an urgent question in the 
M. abscessus field. Our recent development of a reinfection CF mouse model indicates 
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that the reinfection process is able to inhibit host immunity to control the infection 
and allow for M. abscessus to grow and persist in the lung. The exogenous 
reinfection contributes to the development of increased bacterial burden and organ 
pathology. This thesis is intended to understanding M. abscessus pulmonary infection in 
CF mouse models which might also lead to new therapeutic treatments and the better 
understanding of the interaction between CF immune system and the progression of 
bacterial infection, and how they contributed to the chronic inflammation leading to other 
CF conditions. 
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LIST OF ABBREVIATIONS 
 
 
 
AFB             Acid Fast Bacillus 
ANOVA          Analysis of variance 
AP-1             Activator Protein-1 
ASL             Airway Surface Liquid 
BAL             Bronchoalveolar lavage 
BSL-2             biosafety level 2 
BSL-3             biosafety level 3 
C57bl/6          C57 black 6  
cAMP             Cyclic adenosine monophosphate 
CCL-2            C-C motif chemokine ligand 2 
CCL-3            C-C motif chemokine ligand 3 
CXCL-1          C-X-C motif chemokine ligand 1 
CXCL-2          C-X-C motif chemokine ligand 2 
CXCL-8          C-X-C motif chemokine ligand 8 
CF                  Cystic Fibrosis 
CFTR             Cystic Fibrosis Transmembrane Conductance Regulator  
CFTR KO       Cystic Fibrosis Transmembrane Conductance Regulator knockout 
CFU             Colony forming units 
CO2             Carbon dioxide 
Ca+                     Calcium ion 
Cl-                       Chloride ion 
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CLSI                   The Clinical and Laboratory Standard Institute 
ER                 Endoplasmic Reticulum 
erm                Erythromycin Ribosome Methyltransferase 
ENaC             Epithelium Sodium Channel 
ER             Endoplasmic Reticulum 
FABP             Fatty acid-binding protein gene 
Foxi1             Forkhead box I1 
GKO             Gamma-Interferon knockout 
GM-CSF         Granulocyte-Macrophage Colony-Stimulating Factor 
HCO3–            Bicarbonate ion 
H&E             Hematoxylin and Eosin 
IFNs             Interferons 
IFN-α             Interferon- α 
IFN-β             Interferon-β 
IL-1β              Interleukin-1β 
IL-8                Interleukin-8 
IL-10              Interleukin-10 
iNOS             Inducible nitric oxide synthase 
LAR             Lab Animal Resources 
Lep             Leptin 
LPS             Lipopolysaccharide 
MAPK            Mitogen-activated protein kinase 
MCP-1            Monocyte chemoattractant cytokine-1 
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MDR               Multidrug resistance 
MyD88           Myeloid differentiation primary response gene 88 
Na+                 Sodium ion 
NET                Neutrophil extracellular trap 
NF-κB            Nuclear factor kappa-light-chain-enhancer of activated B cells 
NFAT             Nuclear factor of Activated T cells 
NOS              Nitric Oxide Synthase 
NTM             Non-tuberculous Mycobacteria 
OADC            Dubos Oleic Albumin Complex 
OD             Optical density 
PAMPs          Pathogen-associated molecular patterns 
PBS             Phosphate Buffered Saline 
PMN             Polymorphonuclear neutrophils 
rpm             Revolutions per minute 
rRNA             Ribosomal RNA 
SCID             Severe Combined Immunodeficient 
SEM             Standard Error of the Mean 
SOD             Superoxide Dismutase 
TLRs             Toll-Like Receptors 
TLR4             Toll-Like Receptor 4 
TNF- α           Tumor Necrosis Factor alpha 
TNFR             Tumor Necrosis Factor Receptor 
TRIF             TIR-domain-containing adapter-inducing interferon- β 
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TSA             Tryptic Soy Agar  
V-ATPase      Vacuolar Proton-ATPase 
